## Classifiers!!!


BCH394P/364C Systems Biology / Bioinformatics Edward Marcotte, Univ of Texas at Austin


**Clustering** = task of <u>grouping</u> a set of objects in such a way that objects in the same group (a **cluster**) are more similar (in some sense) to each other than to those in other groups (clusters).


VS.


**Classification** = task of <u>categorizing</u> a new observation, on the basis of a training set of data with observations (or instances) whose categories are known

Adapted from Wikipedia









# We also needed a measure of the similarity between feature vectors. Here are a few (of many) common distance measures used in clustering.

Names	Formula
Euclidean distance	$  a - b  _2 = \sqrt{\sum_i (a_i - b_i)^2}$
Manhattan distance	$  a - b  _1 = \sum_i  a_i - b_i $
cosine similarity	$\frac{a \cdot b}{\ a\  \ b\ }$


Wikipedia


We also needed a measure of the similarity between feature vectors. Here are a few (of many) common distance measures used in clustering.


classifying


Names	Formula
Euclidean distance	$  a - b  _2 = \sqrt{\sum_i (a_i - b_i)^2}$
	7   5   7
Manhattan distance	$  a-b  _1 = \sum_i  a_i - b_i $
accine cimilarity	$a \cdot b$
cosine similarity	a   b


Wikipedia




















#### Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring

Let's look at a specific historic example:

T. R. Golub, <sup>1,2</sup>\*† D. K. Slonim, <sup>1</sup>† P. Tamayo, <sup>1</sup> C. Huard, <sup>1</sup> M. Gaasenbeek, <sup>1</sup> J. P. Mesirov, <sup>1</sup> H. Coller, <sup>1</sup> M. L. Loh, <sup>2</sup> J. R. Downing, <sup>3</sup> M. A. Caligiuri, <sup>4</sup> C. D. Bloomfield, <sup>4</sup> E. S. Lander<sup>1,5</sup>\*

"Enzyme-based histochemical analyses were introduced in the 1960s to demonstrate that some leukemias were periodic acid-Schiff positive, whereas others were myeloperoxidase positive...

This provided the first basis for classification of acute leukemias into those arising

from <u>lymphoid</u> precursors (acute lymphoblastic leukemia, ALL), or from myeloid precursors (acute myeloid leukemia, AML)."

15 OCTOBER 1999 VOL 286 SCIENCE

#### Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring

T. R. Golub, <sup>1,2</sup>\* D. K. Slonim, <sup>1</sup>† P. Tamayo, <sup>1</sup> C. Huard, <sup>1</sup> M. Gaasenbeek, <sup>1</sup> J. P. Mesirov, <sup>1</sup> H. Coller, <sup>1</sup> M. L. Loh, <sup>2</sup> J. R. Downing, <sup>3</sup> M. A. Caligiuri, <sup>4</sup> C. D. Bloomfield, <sup>4</sup> E. S. Lander <sup>1,5</sup>\*

# Let's look at a specific historic example:

### "Distinguishing ALL from AML is critical for successful treatment...

chemotherapy regimens for ALL generally contain corticosteroids, vincristine, methotrexate, and L-asparaginase, whereas

most AML regimens rely on a backbone of daunorubicin and cytarabine (8).


Although remissions can be achieved using ALL therapy for AML (and vice versa), <u>cure rates are markedly diminished</u>, and unwarranted toxicities are encountered."

15 OCTOBER 1999 VOL 286 SCIENCE

#### Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring


T. R. Golub, <sup>1,2</sup>\*† D. K. Slonim, <sup>1</sup>† P. Tamayo, <sup>1</sup> C. Huard, <sup>1</sup> M. Gaasenbeek, <sup>1</sup> J. P. Mesirov, <sup>1</sup> H. Coller, <sup>1</sup> M. L. Loh, <sup>2</sup> J. R. Downing, <sup>3</sup> M. A. Caligiuri, <sup>4</sup> C. D. Bloomfield, <sup>4</sup> E. S. Lander<sup>1,5</sup>\*

# Let's look at a specific historic example:



$$gene_1 = (e_1, e_2, e_3, ..., e_{12})$$

gene<sub>2</sub> = 
$$(e_1, e_2, e_3, ..., e_{12})$$




Take labeled samples, find genes whose abundances separate the samples...

15 OCTOBER 1999 VOL 286 SCIENCE

#### Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring


T. R. Golub, <sup>1,2</sup> D. K. Slonim, <sup>1</sup>† P. Tamayo, <sup>1</sup> C. Huard, <sup>1</sup> M. Gaasenbeek, <sup>1</sup> J. P. Mesirov, <sup>1</sup> H. Coller, <sup>1</sup> M. L. Loh, <sup>2</sup> J. R. Downing, <sup>3</sup> M. A. Caligiuri, <sup>4</sup> C. D. Bloomfield, <sup>4</sup> E. S. Lander <sup>1,5</sup>\*


# Let's look at a specific historic example:



Calculate weighted average of indicator genes to assign class of an unknown

15 OCTOBER 1999 VOL 286 SCIENCE






## **Cross-validation**

Withhold a sample, build a predictor based only on the remaining samples, and predict the class of the withheld sample.

Repeat this process for each sample, then calculate the cumulative or average error rate.

15 OCTOBER 1999 VOL 286 SCIENCE



## **Independent data**

Withhold <u>an entire dataset</u>, build a predictor based only on the remaining samples (the training data).

Test the trained classifier on the independent test data to give a fully independent measure of performance.

15 OCTOBER 1999 VOL 286 SCIENCE

You already know how to measure how well these algorithms work (way back in our discussion of gene finding!)...


#### True answer:


# Algorithm predicts:


	Positive	Negative
Positive	True positive	False positive
Negative	False negative	True negative


Specificity = TP / (TP + FP)

Sensitivity = TP / (TP + FN)










## **ROC** versus Recall/Precision

The 2 measures are related and both useful. They differ strongly in performance as proportions of positive and negative classes change.




Thanks to Dariya Sydykova (UT Austin), for her excellent visualizations, available here: https://github.com/dariyasydykova/open\_projects/tree/master/ROC\_animation

## **ROC** versus Recall/Precision

- R/P depends <u>strongly</u> on relative rates of the 2 classes
- ROC performance is <u>independent</u> of their relative rates

(It may be important or not for your particular problem...)



Thanks to Dariya Sydykova (UT Austin), for her excellent visualizations, available here: https://github.com/dariyasydykova/open\_projects/tree/master/ROC\_animation



BinaxNOW™ COVID-19 Ag Card Performance within 7 days of symptom onset against the Comparator Method


BinaxNOW™ COVID-19 Ag Card		Con	nparator Me	thod
		Positive	Negative	Total
	Positive	99	5	104
	Negative	18	338	356
	Total	117	343	460
	Positive Agreement: 99/117 84.	6% (95% CI	: 76.8% - 90	).6%)
	Negative Agreement: 338/343 9	8.5% (95% (	CI: 96.6% -	99.5%)




Any guesses why?


Hint: How would COVID test performance change for ROC vs Precision/Recall as the infection rate in the population changes?


https://www.fda.gov/media/141570/download





Would it work well for this data?











Back to leukemias. There was a followup study in 2010: Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

Torsten Haferlach, Alexander Kohlmann, Lothar Wieczorek, Giuseppe Basso, Geertruy Te Kronnie, Marie-Christine Bené, John De Vos, Jesus M. Hernández, Wolf-Karsten Hofmann, Ken I. Mills, Armanda Gilkse, Sabina Chiarett, Sheila A. Shurtleff, Thomas J. Kipps, Laura Z. Rassenti, Allen E. Yeoh, Peter R. Papenhausen, Wei-min Liu, P. Mickey Williams, and Robin Foà

- Tested clinical use of expression profiling to subtype leukemias
- Meta-analysis of 11 labs, 3 continents, 3,334 patients
- Stage 1 (2,096 patients): 92.2% classification accuracy for 18 leukemia classes (99.7% median specificity)
- Stage 2 (1,152 patients):
   95.6% median sensitivity and 99.8% median specificity for 14 subtypes of acute leukemia
- Microarrays outperformed routine diagnostics in 29 (57%) of 51 discrepant cases

Conclusion: "Gene expression profiling is a robust technology for the diagnosis of hematologic malignancies with high accuracy"

J Clin Oncol 28:2529-2537. © 2010

# Current commercial breast cancer gene expression panels use this same strategy

Summary of breast cancer commercially available gene expression signatures.							
Gene Signature	Biomarker Sources	Analysis Type	Clinical Outcome	No. Genes	Reference		
Oncotype DX Breast	Breast tumor tissue	mRNA	Survival, benefit of chemotherapy	21	2004 Paik [ <u>82]</u>		
Mammaprint	Breast tumor tissue	mRNA	Survival	70	2002 van't Veer [ <u>83</u> ]		
Endopredict	Breast tumor tissue	mRNA	Survival	12	2017 Warf [ <u>84]</u>		
Prosigna/PAM50	Breast tumor tissue	mRNA	Survival	50	2009 Parker [ <u>85</u> ]		
Breast Cancer Index	Breast tumor tissue	mRNA	Survival, benefit of hormone therapy after 5 years	7	2008 Ma, 2013 Sgroi [ <u>86,87]</u>		

Prognostic Cancer Gene Expression Signatures: Current Status and Challenges (2021) Cells 10(3): 648

In practice, if you want to explore classifiers, I also <u>strongly</u> recommend always testing these classifiers:


# Random forests Support vector machines (SVM)

These two are surprisingly often the best for many biological classification problems. Weka can do both of them.

- → Note that I didn't say neural networks. Deep neural networks can be extremely powerful (e.g. AlphaFold) but usually require extensive training examples. In general, you'll often be better off starting off with the above classifiers for many problems, only moving to deep neural networks if you really need to and when you have data to support it.
- → We'll talk about NNs in the next 2 lectures, including large language models.


The two-slide overview of Random forest classifiers:

- (1) Construct many decision trees from random subsets of your features. Because the features vary across trees, trees tend to be weak but uncorrelated
- (2) All the trees "vote" on the answer, majority wins.




The two-slide overview of **Random forest classifiers:** 


- (1) Construct many decision trees from random subsets of your features. Because the features vary across trees, trees tend to be weak but uncorrelated
- (2) All the trees "vote" on the answer, majority wins.




The one-slide overview of **Support vector machines:** 


(1) Goal: make a linear classifier, choosing a decision boundary that *maximizes* the *distance margin* between classes







(2) But what if the boundary is non-linear? Use *kernels* to implicitly map the data to higher dimension where a linear decision can be made



In practice, if you want to explore classifiers, I <u>strongly</u> recommend the Weka package:

http://www.cs.waikato.ac.nz/ml/weka/



It's free, and easy to install, use, & troubleshoot. It lets you quickly test many alternative (well-vetted) classifiers, all in a proper cross-validated/precision-recall framework.

Here's a nice step-by-step intro for biologists: Introducing Machine Learning Concepts with WEKA, in *Statistical Genomics, Methods in Molecular Biology*, v. 1418, p. 353-378, 24 March 2016

http://link.springer.com/content/pdf/10.1007%2F978-1-4939-3578-9\_17.pdf



There's also a great book to walk you through the entire process.

Highly recommended!!!



I recommend combining it with the Pandas library for data analysis to make it easy to work with big, tabular datasets: https://pandas.pydata.org/

## Coming up:

The next two lectures will be guest lectures covering the basics of deep neural networks, with talks on

Protein 3D structural modeling and prediction w/ AlphaFold/ChimeraX

DeepNNs, Large Language Models, & ESM